These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25449964)

  • 21. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
    Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis.
    Liu C; Blumhardt LD
    Mult Scler; 2002 Feb; 8(1):10-4. PubMed ID: 11936481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
    Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
    Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon β.
    Melanson M; Grossberndt A; Klowak M; Leong C; Frost EE; Prout M; Le Dorze JA; Gramlich C; Doupe M; Wong L; Esfahani F; Gomori A; Namaka M
    Int J Neurosci; 2010 Oct; 120(10):631-40. PubMed ID: 20942577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-beta in multiple sclerosis causing thrombotic microangiopathy.
    Yam C; Fok A; Mclean C; Butler E; Kempster P
    Intern Med J; 2019 Feb; 49(2):274-276. PubMed ID: 30754081
    [No Abstract]   [Full Text] [Related]  

  • 31. Thrombotic microangiopathy due to acquired complement factor I deficiency in a male receiving interferon-beta treatment for multiple sclerosis.
    Mrabet S; Dahmane R; Raja B; Fradi A; Aicha NB; Sahtout W; Azzabi A; Guedri Y; Zellama D; Achour A; Sfar I; Goucha R; Abdessayed N; Mokni M
    Br J Clin Pharmacol; 2023 May; 89(5):1682-1685. PubMed ID: 36480744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β.
    Larochelle C; Grand'maison F; Bernier GP; Latour M; Cailhier JF; Prat A
    Mult Scler; 2014 Nov; 20(13):1783-7. PubMed ID: 24534079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Interferon ß, nephrotic syndrome and thrombotic microangiopathy].
    Quintana LF; Campistol JM
    Med Clin (Barc); 2015 Jan; 144(2):65-6. PubMed ID: 25458512
    [No Abstract]   [Full Text] [Related]  

  • 36. Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
    Pandya R; Patten S
    Can J Psychiatry; 2002 Sep; 47(7):686. PubMed ID: 12355685
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
    Lus G; Signoriello E; Maniscalco GT; Bonavita S; Signoriello S; Gallo C
    Eur J Neurol; 2016 Mar; 23(3):489-93. PubMed ID: 26212486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comment on thrombotic microangiopathy induced by interferon-β therapy.
    Cavoli GL; Passantino R; Tortorici C; Bono L; Ferrantelli A; Rotolo U
    Clin Nephrol; 2012 Dec; 78(6):506-7. PubMed ID: 23164420
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.